Valeritas Holdings Inc. (fka VLRXQ)

[BottomBounce]

$VLRX Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced positive clinical outcomes for V-Go compared to insulin pen devices for treating people with type 2 diabetes prescribed basal-bolus insulin therapy. The results were presented at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019) in Berlin, Germany.

This retrospective study was performed using electronic medical records of 148 patients from nine diabetes centers in the United States. Patients with uncontrolled blood sugar levels (A1c ≥ 7.0%) who were prescribed basal-bolus insulin therapy administered by insulin pen devices prior to using V-Go were included in the evaluation. At the third and seventh month of V-Go use, patients experienced statistically significant reductions in both A1c levels and total daily doses of insulin. A1c levels decreased by 1.04 and 1.11, respectively from a baseline A1c of 9.1%. The average total daily dose of insulin decreased by 25 and 24 units per day, respectively from a baseline dose of 82 units per day. Similar A1c reductions were experienced in patients prescribed > 50 units per day of basal or prandial insulin at baseline.

“We are excited to share these positive data from our clinical study at ATTD 2019,” said John Timberlake, President and Chief Executive Officer of Valeritas. “We believe the results of this study further support when basal-bolus insulin therapy is needed, the use of V-Go Wearable Insulin Delivery device can offer significant clinical benefit.”

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.

http://www.globenewswire.com/news-release/2019/02/21/1739155/0/en/Switching-to-Valeritas-V-Go-Wearable-Insulin-Delivery-Device-from-Insulin-Pen-Devices-for-Basal-Bolus-Therapy-Improved-Glycemic-Control-with-Less-Insulin.html?culture=en-us